)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Gedeon Richter
Gedeon Richter (RICHTER) investor relations material
Gedeon Richter Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary7 Aug, 2026
Executive summary
CER revenue grew 8.7% in H1 2026, with strong performance in CNS, Biotechnology, and improving Women's Healthcare and GenMed, despite significant FX headwinds that led to a 0.5% YoY decline in reported revenues.
Clean EBIT (CER) rose 21% in H1 2026, driven by CNS and Biotech momentum, operational discipline, and efficiency initiatives; reported Clean EBIT up 3% to HUF 151.8bn.
Net profit fell 14% YoY to HUF 103.5bn, mainly due to significant FX losses, despite resilient operating profit.
Free cash flow reached a record HUF 137bn in H1 2026, up 24% YoY, supported by higher operating profits and lower net working capital needs.
Profitability guidance for 2026 was upgraded to double-digit Clean EBIT growth (CER), reflecting strong VraylarⓇ performance and efficiency initiatives.
Financial highlights
CER pharmaceutical revenues up 8.7% in H1 2026; reported revenues at HUF 455.2bn, down 0.5% YoY due to FX headwinds.
Clean EBIT at HUF 151.8bn (EUR 407mn); gross margin declined to 69% (-1.2ppt) due to FX pressure.
EPS at HUF 566, down 13.7% YoY; ROE at 15.8%, down from 17.0% YoY.
Free cash flow up 24% YoY to HUF 137bn; CapEx at HUF 10bn in H1.
Net profit margin declined due to significant FX losses.
Outlook and guidance
2026 Clean EBIT guidance (CER) upgraded to double-digit growth following strong H1 profitability.
Pharma CER revenue guidance maintained at high-single-digit growth for 2026.
FX headwind for the full year expected to remain at 7%-8%, with less impact in H2.
Continued focus on innovative portfolio expansion and operational efficiency.
Mid-single-digit growth anticipated from 2027, with GenMed recovery expected.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Gedeon Richter
- Pharma growth lifted clean EBIT, but FX losses and taxes cut net profit.RICHTER
Q4 2023 - Strong H1 2026 growth, innovation pipeline, and sustainability drive long-term value.RICHTERInvestor presentation
- Women's Healthcare and Biotech drive growth as Vraylar® and biosimilars outperform in Q1 2026.RICHTERInvestor presentation
- Q1 2026 saw 5.9% CER growth, 15% Clean EBIT rise, but FX and net profit declines.RICHTERQ1 2026
- Strong 2025 results with robust growth in Women's Health and innovation, outlook remains positive.RICHTERQ4 2025
- Revenue up 10.9–11%, Clean EBIT up 14.5–15.1%, but net profit down 13.2%.RICHTERQ2 2025
- Acquisitions and innovation accelerate growth toward European leadership in women’s healthcare.RICHTERInvestor Update
- Strong Q1 growth, record cash flow, and four biosimilar launches planned in next 12 months.RICHTERQ1 2025
- Record 2024 growth and cash flow; 2025 targets 10% gains with cost and R&D focus.RICHTERQ4 2024
Next Gedeon Richter earnings date
Q3 202610 Nov, 2026
Gedeon Richter
Next Gedeon Richter earnings date
Q3 202610 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. is a Hungary-based pharmaceutical company engaged in the research, development, manufacture, marketing, and sale of a wide range of pharmaceutical products globally. The company focuses on several therapeutic areas including women's healthcare, central nervous system disorders, and cardiovascular diseases. It also offers a variety of over-the-counter products. The company is known for its commitment to providing innovative healthcare solutions and services. Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. was founded in 1901 and is headquartered in Budapest, Hungary, and its shares are listed on the Budapest Stock Exchange .